187 related articles for article (PubMed ID: 33172520)
1. Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB.
Cox V; McKenna L; Acquah R; Reuter A; Wasserman S; Vambe D; Ustero P; Udwadia Z; Triviño-Duran L; Tommasi M; Skrahina A; Seddon JA; Rodolfo R; Rich M; Padanilam X; Oyewusi L; Ohler L; Lungu P; Loveday M; Khan U; Khan P; Hughes J; Hewison C; Guglielmetti L; Furin J
Int J Tuberc Lung Dis; 2020 Nov; 24(11):1134-1144. PubMed ID: 33172520
[TBL] [Abstract][Full Text] [Related]
2. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
[TBL] [Abstract][Full Text] [Related]
3. Shortened tuberculosis treatment regimens: what is new?
Silva DR; Mello FCQ; Migliori GB
J Bras Pneumol; 2020; 46(2):e20200009. PubMed ID: 32215450
[TBL] [Abstract][Full Text] [Related]
4. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.
Habimana DS; Ngabonziza JCS; Migambi P; Mucyo-Habimana Y; Mutembayire G; Byukusenge F; Habiyambere I; Remera E; Mugwaneza P; Mwikarago IE; Mazarati JB; Turate I; Nsanzimana S; Decroo T; de Jong CB
Am J Trop Med Hyg; 2021 May; 105(1):47-53. PubMed ID: 33999845
[TBL] [Abstract][Full Text] [Related]
6. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
[TBL] [Abstract][Full Text] [Related]
7. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
8. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
[TBL] [Abstract][Full Text] [Related]
9. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
[TBL] [Abstract][Full Text] [Related]
10. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
[TBL] [Abstract][Full Text] [Related]
11. Update of drug-resistant tuberculosis treatment guidelines: A turning point.
Vanino E; Granozzi B; Akkerman OW; Munoz-Torrico M; Palmieri F; Seaworth B; Tiberi S; Tadolini M
Int J Infect Dis; 2023 May; 130 Suppl 1():S12-S15. PubMed ID: 36918080
[TBL] [Abstract][Full Text] [Related]
12. Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment.
Seddon JA; Johnson S; Palmer M; van der Zalm MM; Lopez-Varela E; Hughes J; Schaaf HS
Expert Rev Respir Med; 2021 Feb; 15(2):221-237. PubMed ID: 32965141
[TBL] [Abstract][Full Text] [Related]
13. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
[TBL] [Abstract][Full Text] [Related]
14. MDR Tuberculosis Treatment.
Espinosa-Pereiro J; Sánchez-Montalvá A; Aznar ML; Espiau M
Medicina (Kaunas); 2022 Jan; 58(2):. PubMed ID: 35208510
[TBL] [Abstract][Full Text] [Related]
15. Ongoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children
McQuaid CF; Cohen T; Dean AS; Houben RMGJ; Knight GM; Zignol M; White RG
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 32855219
[TBL] [Abstract][Full Text] [Related]
16. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
Falzon D; Schünemann HJ; Harausz E; González-Angulo L; Lienhardt C; Jaramillo E; Weyer K
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331043
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach.
Schaaf HS
Indian J Pediatr; 2019 Aug; 86(8):717-724. PubMed ID: 30656560
[TBL] [Abstract][Full Text] [Related]
18. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
Tembo BP; Malangu NG
BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013-2015: A retrospective cohort study.
Chaves-Torres NM; Fadul S; Patiño J; Netto E
PLoS One; 2021; 16(4):e0249565. PubMed ID: 33852619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
